21 to 30 of 3,436 Results
PNG Image - 44.5 KB -
MD5: cc19fc71c697aad857122ff12c0b75cd
|
Postscript - 14.4 KB -
MD5: daa2b5a27f728092edc96e11d8deaeab
|
PNG Image - 35.4 KB -
MD5: c1209c6d11a3278d99277ddb14e138ae
|
Postscript - 14.6 KB -
MD5: dbf129cecec915905d3a3c8bcf20936d
|
PNG Image - 39.6 KB -
MD5: 8ee4c272ebcd5af19a8a90deeef59ec1
|
Postscript - 14.2 KB -
MD5: 36657d255f6c128af4844033530cf6bd
|
PNG Image - 37.4 KB -
MD5: 3abc253e2f2ab6b30e048b489669eacf
|
Adobe PDF - 319.6 KB -
MD5: e1c75b94f14563cb1861efc5023ce9a7
Copy of the paper |
Plain Text - 3.3 KB -
MD5: 13723cc3db81e58c4a94f4409b3e91ec
README file with description of the contents (script functions, variable names etc) |
Jul 3, 2026 - BSMI andmed
Hickey, Miriam A., 2026, "Data for Nanoformulated bisdemethoxycurcumin does not ameliorate pathology or cognitive impairment in 5xFAD transgenic mice", https://doi.org/10.23673/HKYC8R, DATADOI, V1, UNF:6:fnILGjjIuosqDx0MeXewgQ== [fileUNF]
Dementia and dementia-related diseases are a growing societal burden, and they remain largely incurable. Antibody therapies are very costly and their limited accessibility and efficacy underscore the significant continuing importance of small molecule therapeutics. Curcuminoids are of great interest in neurodegenerative diseases, in particular in A... |
